Cargando…

Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics

In previous work we developed a pharmacogenetic predictor of antipsychotic (AP) induced extrapyramidal symptoms (EPS) based on four genes involved in mTOR regulation. The main objective is to improve this predictor by increasing its biological plausibility and replication. We re-sequence the four ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boloc, Daniel, Gortat, Anna, Cheng-Zhang, Jia Qi, García-Cerro, Susana, Rodríguez, Natalia, Parellada, Mara, Saiz-Ruiz, Jeronimo, Cuesta, Manolo J., Gassó, Patricia, Lafuente, Amalia, Bernardo, Miquel, Mas, Sergi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293322/ https://www.ncbi.nlm.nih.gov/pubmed/30546092 http://dx.doi.org/10.1038/s41398-018-0330-4

Ejemplares similares

Author Correction: Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics
por: Boloc, Daniel, et al.
Publicado: (2019)

Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data
por: Martínez-Pinteño, Albert, et al.
Publicado: (2021)

Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls
por: Batalla, A, et al.
Publicado: (2015)

Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder
por: Rodríguez, Natalia, et al.
Publicado: (2017)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
por: Bioque, Miquel, et al.
Publicado: (2015)

Pharmacogenetics and outcome with antipsychotic drugs
por: Pouget, Jennie G., et al.
Publicado: (2014)

Integrating Genetic, Neuropsychological and Neuroimaging Data to Model Early-Onset Obsessive Compulsive Disorder Severity
por: Mas, Sergi, et al.
Publicado: (2016)

Correction: Integrating Genetic, Neuropsychological and Neuroimaging Data to Model Early-Onset Obsessive Compulsive Disorder Severity
por: Mas, Sergi, et al.
Publicado: (2017)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Satisfaction survey with DNA cards method to collect genetic samples for pharmacogenetics studies
por: Vidal-Taboada, Jose M, et al.
Publicado: (2006)

Pharmacogenetics of antipsychotic-induced side effects
por: Lencz, Todd, et al.
Publicado: (2009)

The Pharmacogenetics of Symptom Response to Antipsychotic Drugs
por: Reynolds, Gavin P
Publicado: (2012)

EXPERIENCE OF PHARMACOGENETIC TESTING IN THE TREATMENT OF ANTIPSYCHOTICS
por: Kaydan, M., et al.
Publicado: (2023)

ANTIPSYCHOTIC-INDUCED VACUOUS CHEWING MOVEMENTS AND EXTRAPYRAMIDAL SIDE-EFFECTS ARE HIGHLY HERITABLE IN MICE
por: Crowley, James J., et al.
Publicado: (2010)

Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D(2) receptors
por: Sykes, David A., et al.
Publicado: (2017)

Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia
por: Weng, Jiajun, et al.
Publicado: (2019)

Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects
por: Ohno, Yukihiro, et al.
Publicado: (2019)

DNA Methylation of Fluoxetine Response in Child and Adolescence: Preliminary Results
por: Martinez-Pinteño, Albert, et al.
Publicado: (2021)

Integrative DNA Methylation and Gene Expression Analysis of Cognitive Behavioral Therapy Response in Children and Adolescents with Obsessive-Compulsive Disorder; a Pilot Study
por: Rodriguez, Natalia, et al.
Publicado: (2021)

Antipsychotics with similar association kinetics at dopamine D(2) receptors differ in extrapyramidal side-effects
por: Zeberg, Hugo, et al.
Publicado: (2018)

Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies
por: Ali, Tilahun, et al.
Publicado: (2021)

Reply to ‘Antipsychotics with similar association kinetics at dopamine D(2) receptors differ in extrapyramidal side-effects’
por: Sykes, David A., et al.
Publicado: (2018)

Differentiating Between Lithium Tremors and Extrapyramidal Tremors in a Patient on Long-Term Antipsychotics and Lithium Medication
por: Singh, Gurraj, et al.
Publicado: (2023)

Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations
por: Eum, Seenae, et al.
Publicado: (2016)

Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients
por: Rodríguez, Natalia, et al.
Publicado: (2022)

Systematic Review of the Therapeutic Role of Apoptotic Inhibitors in Neurodegeneration and Their Potential Use in Schizophrenia
por: Morén, Constanza, et al.
Publicado: (2022)

Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2021)

A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments
por: Arranz, Maria J., et al.
Publicado: (2019)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
por: Toja-Camba, Francisco José, et al.
Publicado: (2021)

Drug-Induced Extrapyramidal Syndromes
por: Lader, M. H.
Publicado: (1970)

Escitalopram-induced extrapyramidal symptoms
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2019)

A retrospective study of extrapyramidal syndromes with second generation antipsychotics in the psychiatric unit of a tertiary care teaching hospital
por: Lahon, Kingshuk, et al.
Publicado: (2012)

Cariprazine as a useful treatment for patients with schizophrenia and antipsychotic-induced extrapyramidal symptoms: a case report and literature review
por: Llach, C., et al.
Publicado: (2022)

Neurotoxic/Neuroprotective Effects of Clozapine and the Positive Allosteric Modulator of mGluR2 JNJ-46356479 in Human Neuroblastoma Cell Cultures
por: Gassó, Patricia, et al.
Publicado: (2023)

The Effect of Clozapine and Novel Glutamate Modulator JNJ-46356479 on Nitrosative Stress in a Postnatal Murine Ketamine Model of Schizophrenia
por: Treder, Nina, et al.
Publicado: (2023)

Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation
por: Lerer, Bernard, et al.
Publicado: (2006)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Genetic Variants in Diseases of the Extrapyramidal System
por: Oczkowska, Anna, et al.
Publicado: (2014)

Akathisia as an Extrapyramidal Side Effect of Fluoxetine
por: Ajufo, Ijeoma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gq9u1soicask3b7km98q91ahja